Profound Medical Corp.
NASDAQ:PROFMedical - Devices
+$0.27 today
- Market cap
- $253.09M
- Beta
- 0.52
- P/E (TTM)
- -6.3
- EPS (TTM)
- -$1.07
Volume 0.08M
Average 0.12M
PROF Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Profound Medical Corp.NASDAQ: PROF
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $5.19M rose 8.3% year over year, ahead of the -1.0% change in trailing-twelve-month research & development. Sequentially, it rose 19.6% from the prior quarter. Over 3 fiscal years it compounded at +12.6% a year.
Context
- Research & development amounted to 127.9% of revenue in FY2025, down 30.9 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +8.3% holds above the trailing-twelve-month pace of -1.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 20.96M USD
- Year-over-year change
- +29.8%
- 4-year CAGR
- +8.2%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 20.96M | +29.8% |
| FY2024 | 2024-12-31 | 16.15M | +12.3% |
| FY2023 | 2023-12-31 | 14.38M | -2.1% |
| FY2022 | 2022-12-31 | 14.69M | -3.8% |
| FY2021 | 2021-12-31 | 15.28M | — |
Research & Development vs competitors
How PROF compares with its peers on the latest reported figures
- PROF's LTM Mar 2026 research & development of $21.15M is the 4th highest of the 11 companies compared; the peer median is $16.95M.
- Its year-over-year change of -1.0% is the 5th highest of 11, against a peer median of -3.2%.
- Research & development amounts to 112.1% of revenue for PROF, versus a peer median of 45.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $85.68M | +76.6% | +218.7% | 13864.6% | |
AVRAnteris Technologies Global Corp. | LTM Mar 2026 | $70.12M | +24.4% | +57.8% | 3788.3% |
| LTM Mar 2026 | $24.4M | -23.4% | -12.2% | 824.8% | |
| LTM Mar 2026 | $21.15M | -1.0% | +12.6% | 112.1% | |
| LTM Dec 2025 | $19.24M | -4.7% | -10.1% | 147.7% | |
| LTM Mar 2026 | $18.78M | -12.5% | +2.2% | 58.2% | |
| LTM Mar 2026 | $15.13M | +46.7% | -20.4% | 14.1% | |
| LTM Mar 2026 | $14.89M | -1.7% | -11.2% | 33.2% | |
| LTM Mar 2026 | $6.33M | -47.4% | -11.0% | 4.2% | |
| LTM Mar 2026 | $5.47M | +1.0% | -21.9% | 9.5% | |
| LTM Mar 2026 | $4.57M | -56.9% | -5.0% | 4.0% | |
| Peer median (excluding PROF) | $16.95M | -3.2% | -10.6% | 45.7% | |
Competitors are the stored peer set for PROF. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 6.87M | 6.68M | 7.2M | 10.17M | 16.38M |
| Cost of Revenue | 3.92M | 3.66M | 2.82M | 3.47M | 4.79M |
| Gross Profit | 2.95M | 3.02M | 4.38M | 6.7M | 11.59M |
| Gross Margin | 43.0% | 45.2% | 60.9% | 65.9% | 70.8% |
| Research & Development | 15.28M | 14.69M | 14.38M | 16.15M | 20.96M |
| Selling, General & Admin | 17.97M | 17.93M | 18.62M | 22.02M | 32.61M |
| Operating Expenses | 33.24M | 35.15M | 33M | 38.17M | 53.57M |
| Depreciation & Amortization | 1.88M | 1.6M | 1.15M | 891.06K | 569.8K |
| EBITDA | (28.65M) | (26.6M) | (26.78M) | (25.59M) | (41.41M) |
| EBITDA Margin | -416.8% | -398.2% | -372.0% | -251.7% | -252.8% |
| Operating Income | (30.29M) | (32.13M) | (28.62M) | (31.47M) | (41.98M) |
| Operating Margin | -440.7% | -480.9% | -397.5% | -309.6% | -256.3% |
| Interest Income | 203.2K | 1.05M | 1.64M | 1.37M | 1.09M |
| Interest Expense | 66.41K | 167.11K | 770K | 0 | 0 |
| Other Income / Expenses | (303K) | 3.74M | (81K) | 4.99M | (1.08M) |
| Income Before Tax | (30.59M) | (28.38M) | (28.7M) | (26.48M) | (43.06M) |
| Pre-Tax Margin | -445.1% | -424.8% | -398.6% | -260.5% | -262.9% |
| Income Tax Expense | 105K | 287K | (128K) | (1.9K) | 256.41K |
| Net Income | (30.7M) | (28.67M) | (28.57M) | (26.48M) | (43.32M) |
| Net Margin | -446.7% | -429.1% | -396.8% | -260.4% | -264.4% |
| EPS (Basic) | (1.50) | (1.38) | (1.35) | (1.07) | (1.43) |
| EPS (Diluted) | (1.50) | (1.38) | (1.35) | (1.07) | (1.43) |
| Weighted Avg Shares | 20.46M | 20.83M | 21.18M | 24.77M | 30.23M |
| Weighted Avg Shares (Diluted) | 20.47M | 20.83M | 21.18M | 24.77M | 30.23M |
Profound Medical Corp.
NASDAQ:PROF
Intrinsic Alpha fair value
Locked
Current Price
$6.91
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.